Aortic Valve Insufficiency Clinical Trial
Official title:
Effect of Bivalirudin on Aortic Valve Intervention Outcomes 2/3 (BRAVO 2/3)
This is an international, multicenter, open-label, randomized controlled trial. All patients undergoing transfemoral TAVR at the participating centers will be eligible. All sites will initiate enrolment with 2 feasibility roll-in bivalirudin treated patients and thereafter patients will be randomly assigned to either standard dosing of bivalirudin or UFH as control. The 2 roll-in cases per site will constitute the feasibility cohort that will be followed and analyzed separately. Patients will undergo TAVR according to current standard of care practices at the treating centers. Use of antiplatelet agents pre, during, and post procedure, and possibly oral anticoagulants post procedure, will be according to the sites' standard practice. ALL available data will be collected in the eCRF prospectively
This study will be an international, multi-center, open-label, randomized controlled trial in patients undergoing TAVR. Following the conclusion of the roll-in phase of 2 patients per site, who will comprise the feasibility cohort of approximately 70 patients, 550 patients will be randomized to bivalirudin or UFH at approximately 35 centers. Informed consent will be obtained from patients meeting the inclusion criteria before the initiation of any study-specific procedures. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04149600 -
Identification of Genetic Causes of Calcific Aortic Valve Disease
|
||
Enrolling by invitation |
NCT04035356 -
HAART Annuloplasty Device Valve Repair Registry
|
||
Unknown status |
NCT01201070 -
Study of Administration Of Antithrombin in Patients With Low Plasmatic Levels of Antithrombin After Cardiac Surgery
|
Phase 4 | |
Active, not recruiting |
NCT04281771 -
Assessment of Paravalvular Leak After TAVI by Hemodynamic Measurements and Cardiac MRI
|
N/A | |
Completed |
NCT03644784 -
Protocoled Quantitative Assessment of Aortic Regurgitation Using Videodensitometry in a Multicontinental Trial in Rotterdam, Montreal, Yamaguchi, Segeberg, Amsterdam.
|
||
Recruiting |
NCT02288871 -
Pilot Trial: Comparison of Flow Patterns
|
N/A | |
Completed |
NCT01171625 -
Carpentier-Edwards PERIMOUNT Magna Ease Pericardial Bioprosthesis, Model 3300TFX
|
N/A | |
Terminated |
NCT00598598 -
Echocardiographic Assessment of Cardiovascular Changes in Long Term Space Flight
|
N/A | |
Recruiting |
NCT05295628 -
Evaluation of Safety and Effectiveness of the EMBLOK EPS During TAVR
|
N/A | |
Recruiting |
NCT06034028 -
J-Valve TF Early Feasibility Study
|
N/A | |
Recruiting |
NCT06295068 -
Evaluation of ARi With OpSens SavvyWire
|
||
Completed |
NCT05742789 -
Effect of Anesthetics on Troponin I and С-reactive Protein
|
Phase 1 | |
Recruiting |
NCT05172973 -
ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves
|
N/A | |
Completed |
NCT00727181 -
An Observational, Prospective Evaluation of the Trifecta™ Valve
|
N/A | |
Active, not recruiting |
NCT04415047 -
The JenaValve ALIGN-AR Pivotal Trial
|
N/A | |
Not yet recruiting |
NCT02623907 -
China Valve Registry Study-1
|
N/A | |
Completed |
NCT00475267 -
Aortic Valve Replacement With Trifecta(TM)
|
N/A | |
Completed |
NCT00478803 -
Conservative Aortic Valve Surgery for Aortic Insufficiency and Aneurysms of the Aortic Root. CAVIAAR
|
Phase 3 | |
Completed |
NCT00001314 -
Investigation of Heart Function in Patients With Heart Valve Defects
|
N/A | |
Recruiting |
NCT04047082 -
Online Videodensitometric Assessment of Aortic Regurgitation in the Cath-Lab
|